Background: Esophageal cancer (EC) occurs commonly, especially in Asia, and is the sixth leading cause of cancer deaths worldwide. Recently, great progress has been made in research on the etiology and prevention of EC. Summary: The major risk factors for esophageal squamous cell carcinoma (ESCC) are tobacco smoking and alcohol drinking, which act synergistically. Dietary parameters, including dietary carcinogens and insufficiency of micronutrients, could also be important risk factors in certain areas. A common etiological factor for both EC and some other cancers are low levels of intake of fruits and vegetables. With improvements in diet and drinking water in developing countries, the incidence of ESCC decreased. However, in economically well-developed countries, the incidence of esophageal adenocarcinoma (EAC) has markedly increased in the past 40 years. The major etiological factor for EAC is gastroesophageal reflux, which is also an etiological factor for gastric cardia adenocarcinoma (GCA). In certain areas of China, the occurrence of GCA is closely related to ESCC. Susceptibility genes for EC are starting to be discovered, and this may help to identify high-risk groups that have more need for preventive measures. Mitigation of the risk factors, early detection and treatment of precancerous lesions are effective approaches for prevention. Smoking cessation, avoidance of excessive alcohol, meat and caloric consumption, increasing physical activity and frequent consumption of vegetables and fruits are prudent lifestyle modifications for the prevention of EC as well as other diseases. Key Message: The etiology of EC includes tobacco smoking, alcohol drinking, low levels of intake of fruits and vegetables as well as gastroesophageal reflux and susceptibility genes. Practical Implications: A healthy lifestyle including smoking cessation, increasing physical activity, consumption of vegetables as well as reduction of alcohol intake and caloric consumption are major approaches to the prevention of EC.

Keywords:
Esophageal cancer, Etiology, Prevention
1.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2.
Chen WQ: Incidence, mortality, distribution characteristics and trends of tumor in China; in Zhao P, Wang LD, Li JY (eds): Preventive Oncology. Beijing, People's Medical Publishing House, 2015, pp 127-152.
3.
Cook MB, Chow WH, Devesa SS: Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer 2009;101:855-859.
4.
Kamangar F, Chow WH, Abnet CC, Dawsey SM: Environmental causes of esophageal cancer. Gastroenterol Clin North Am 2009;38:27-57, vii.
5.
Doll R, Peto R, Wheatley K, Gray R, Sutherland I: Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ 1994;309:901-911.
6.
McLaughlin JK, Hrubec Z, Blot WJ, Fraumeni JF Jr: Smoking and cancer mortality among US veterans: a 26-year follow-up. Int J Cancer 1995;60:190-193.
7.
Ishikawa A, Kuriyama S, Tsubono Y, Fukao A, et al: Smoking, alcohol drinking, green tea consumption and the risk of esophageal cancer in Japanese men. J Epidemiol 2006;16:185-192.
8.
Freedman ND, Abnet CC, Leitzmann MF, Mouw T, et al: A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 2007;165:1424-1433.
9.
Boffetta P, Garfinkel L: Alcohol drinking and mortality among men enrolled in an American Cancer Society prospective study. Epidemiology 1990;1:342-348.
10.
Brown LM, Hoover R, Silverman D, Baris D, et al: Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol 2001;153:114-122.
11.
Yang CS: Nitrosamines and other etiological factors in the esophageal cancer in northern China; in Magee PN (ed): Banbury Report 12: Nitrosamines and Human Cancer. New York, Cold Spring Harbor Laboratory, 1982, pp 487-501.
12.
Boffetta P, Hashibe M: Alcohol and cancer. Lancet Oncol 2006;7:149-156.
13.
Freedman ND, Park Y, Subar AF, Hollenbeck AR, et al: Fruit and vegetable intake and esophageal cancer in a large prospective cohort study. Int J Cancer 2007;121:2753-2760.
14.
Yang CS: Research on esophageal cancer in China: a review. Cancer Res 1980;40:2633-2644.
15.
Islami F, Kamangar F, Nasrollahzadeh D, Møller H, et al: Oesophageal cancer in Golestan Province, a high-incidence area in northern Iran - a review. Eur J Cancer 2009;45:3156-3165.
16.
Yang CS, Miao J, Yang W, Huang M, et al: Diet and vitamin nutrition of the high esophageal cancer risk population in Linxian, China. Nutr Cancer 1982;4:154-164.
17.
Yang CS, Sun Y, Yang QU, Miller KW, et al: Vitamin A and other deficiencies in Linxian, a high esophageal cancer incidence area in northern China. J Natl Cancer Inst 1984;73:1449-1453.
18.
Taylor PR, Qiao YL, Abnet CC, Dawsey SM, et al: Prospective study of serum vitamin E levels and esophageal and gastric cancers. J Natl Cancer Inst 2003;95:1414-1416.
19.
Tran GD, Sun XD, Abnet CC, Fan JH, et al: Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer 2005;113:456-463.
20.
Li JY, Ershow AG, Chen ZJ, Wacholder S, et al: A case-control study of cancer of the esophagus and gastric cardia in Linxian. Int J Cancer 1989;43:755-761.
21.
Islami F, Boffetta P, Ren JS, Pedoeim L, et al: High-temperature beverages and foods and esophageal cancer risk - a systematic review. Int J Cancer 2009;125:491-524.
22.
Wen CP, Tsai MK, Chung WS, Hsu HL, et al: Cancer risks from betel quid chewing beyond oral cancer: a multiple-site carcinogen when acting with smoking. Cancer Causes Control 2010;21:1427-1435.
23.
Liyanage SS, Rahman B, Gao Z, Zheng Y, et al: Evidence for the aetiology of human papillomavirus in oesophageal squamous cell carcinoma in the Chinese population: a meta-analysis. BMJ Open 2013;3:e003604.
24.
Cui R, Kamatani Y, Takahashi A, Usami M, et al: Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology 2009;137:1768-1775.
25.
Wang LD, Zhou FY, Li XM, Sun LD, et al: Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies a susceptibility locus at PLCE1. Nat Genet 2010;42:759-763.
26.
Abnet CC, Freedman ND, Hu N, Wang Z, et al: A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet 2010;42:764-767.
27.
Chang J, Wei L, Miao X, Yu D, et al: Two novel variants on 13q22.1 are associated with risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2015;24:1774-1780.
28.
Wu C, Wang Z, Song X, Feng XS, Abnet CC: Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nat Genet 2014;46:1001-1006.
29.
Zhang L, Zhou Y, Cheng C, Cui H, et al: Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am J Hum Genet 2015;96:597-611.
30.
Gao YB, Chen ZL, Li JG, Hu XD, et al: Genetic landscape of esophageal squamous cell carcinoma. Nat Genet 2014;46:1097-1102.
31.
Lin DC, Hao JJ, Nagata Y, Xu L, et al: Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 2014;46:467-473.
32.
Song Y, Li L, Ou Y, Gao Z, et al: Identification of genomic alterations in oesophageal squamous cell cancer. Nature 2014;509:91-95.
33.
Kang X, Chen K, Li Y, Li J, et al: Personalized targeted therapy for esophageal squamous cell carcinoma. World J Gastroenterol 2015;21:7648-7658.
34.
Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-1289.
35.
Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053.
36.
Brown LM, Devesa SS, Chow WH: Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008;100:1184-1187.
37.
Lagergren J, Bergström R, Lindgren A, Nyrén O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831.
38.
Wu AH, Tseng CC, Bernstein L: Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer 2003;98:940-948.
39.
Jankowski JA, Provenzale D, Moayyedi P: Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002;122:588-590.
40.
Hongo M, Nagasaki Y, Shoji T: Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol 2009;24:729-735.
41.
Chen X, Yang G, Ding WY, Bondoc F, et al: An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis 1999;20:1801-1808.
42.
Chen X, Mikhail SS, Ding YW, Yang G, et al: Effects of vitamin E and selenium supplementation on esophageal adenocarcinogenesis in a surgical model with rats. Carcinogenesis 2000;21:1531-1536.
43.
Chen X, Ding YW, Yang G, Bondoc F, et al: Oxidative damage in an esophageal adenocarcinoma model with rats. Carcinogenesis 2000;21:257-263.
44.
Chen X, Yang CS: Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis 2001;22:1119-1129.
45.
Hao J, Zhang B, Liu B, Lee M, et al: Effect of α-tocopherol, N-acetylcysteine and omeprazole on esophageal adenocarcinoma formation in a rat surgical model. Int J Cancer 2009;124:1270-1275.
46.
Chen X, Li N, Wang S, Hong J, et al: Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and α-difluoromethylornithine on tumorigenesis in a rat surgical model. Carcinogenesis 2002;23:2095-2102.
47.
Chen X, Li N, Wang S, Wu N, et al: Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. J Natl Cancer Inst 2003;95:1053-1061.
48.
Chen X, Wang S, Wu N, Sood S, et al: Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis. Clin Cancer Res 2004;10:6703-6709.
49.
Vial M, Grande L, Pera M: Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res 2010;182:1-17.
50.
Percik R, Stumvoll M: Obesity and cancer. Exp Clin Endocrinol Diabetes 2009;117:563-566.
51.
Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL: Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007;133:403-411.
52.
Yasuhara H, Miyake Y, Toyokawa T, Matsumoto K, et al: Large waist circumference is a risk factor for reflux esophagitis in Japanese males. Digestion 2010;81:181-187.
53.
Cook MB, Kamangar F, Whiteman DC, Freedman ND, et al: Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst 2010;102:1344-1353.
54.
El-Serag HB, Lagergren J: Alcohol drinking and the risk of Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 2009;136:1155-1157.
55.
Thompson OM, Beresford SA, Kirk EA, Vaughan TL: Vegetable and fruit intakes and risk of Barrett's esophagus in men and women. Am J Clin Nutr 2009;89:890-896.
56.
Kubo A, Block G, Quesenberry CP Jr, Buffler P, Corley DA: Effects of dietary fiber, fats, and meat intakes on the risk of Barrett's esophagus. Nutr Cancer 2009;61:607-616.
57.
Cross AJ, Freedman ND, Ren J, Ward MH, et al: Meat consumption and risk of esophageal and gastric cancer in a large prospective study. Am J Gastroenterol 2010;106:432-442.
58.
Nguyen TH, Thrift AP, Ramsey D, Green L, et al: Risk factors for Barrett's esophagus compared between African Americans and non-Hispanic Whites. Am J Gastroenterol 2014;109:1870-1880.
59.
Ek WE, Levine DM, D'Amato M, Pedersen NL, et al: Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal reflux. J Natl Cancer Inst 2013;105:1711-1718.
60.
Becker J, May A, Gerges C, Anders M, et al: Supportive evidence for FOXP1, BARX1, and FOXF1 as genetic risk loci for the development of esophageal adenocarcinoma. Cancer Med 2015;4:1700-1704.
61.
Buas MF, Levine DM, Makar KW, Utsugi H, et al: Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis 2014;35:2740-2747.
62.
Levine DM, Ek WE, Zhang R, Liu X, et al: A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet 2013;45:1487-1493.
63.
Lee E, Stram DO, Ek WE, Onstad LE, et al: Pleiotropic analysis of cancer risk loci on esophageal adenocarcinoma risk. Cancer Epidemiol Biomarkers Prev 2015;24:1801-1803.
64.
Buas MF, Onstad L, Levine DM, Risch HA, et al: miRNA-related SNPs and risk of esophageal adenocarcinoma and Barrett's esophagus: post genome-wide association analysis in the BEACON consortium. PLoS One 2015;10:e0128617.
65.
Dulak AM, Stojanov P, Peng S, Lawrence MS, et al: Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013;45:478-486.
66.
Ross-Innes CS, Becq J, Warren A, Cheetham RK, et al: Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet 2015;47:1038-1046.
67.
Stachler MD, Taylor-Weiner A, Peng S, McKenna A, et al: Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet 2015;47:1047-1055.
68.
Weaver JM, Ross-Innes CS, Shannon N, Lynch AG, et al: Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 2014;46:837-843.
69.
Nones K, Waddell N, Wayte N, Patch AM, et al: Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun 2014;5:5224.
70.
Timmer MR, Martinez P, Lau CT, Westra WM, et al: Derivation of genetic biomarkers for cancer risk stratification in Barrett's oesophagus: a prospective cohort study. Gut 2015, Epub ahead of print.
71.
Varghese S, Newton R, Ross-Innes CS, Lao-Sirieix P, et al: Analysis of dysplasia in patients with Barrett's esophagus based on expression pattern of 90 genes. Gastroenterology 2015;149:1511-1518.e5.
72.
Deans C, Yeo MS, Soe MY, Shabbir A, et al: Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome. World J Surg 2011;35:617-624.
73.
Blot WJ, Li J-Y, Taylor PR, Guo W, et al: Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-1491.
74.
Mark SD, Qiao YL, Dawsey SM, Wu YP, et al: Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst 2000;92:1753-1763.
75.
Steevens J, van den Brandt PA, Goldbohm RA, Schouten LJ: Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands Cohort Study. Gastroenterology 2010;138:1704-1713.
76.
Chandanos E, Lagergren J: The mystery of male dominance in oesophageal cancer and the potential protective role of oestrogen. Eur J Cancer 2009;45:3149-3155.
77.
Chandanos E, Lagergren J: Oestrogen and the enigmatic male predominance of gastric cancer. Eur J Cancer 2008;44:2397-2403.
78.
García Rodríguez LA, Lagergren J, Lindblad M: Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 2006;55:1538-1544.
79.
Qiao YL, Dawsey SM, Kamangar F, Fan JH, et al: Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. J Natl Cancer Inst 2009;101:507-518.
80.
Li JY, Taylor PR, Li B, Dawsey S, et al: Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 1993;85:1492-1498.
81.
Limburg PJ, Wei W, Ahnen DJ, Qiao Y, et al: Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 2005;129:863-873.
82.
Lin P: Medicamentous inhibitory therapy of precancerous lesions of the esophagus - 3 and 5 year inhibitory effect of Antitumor B, retinamide and riboflavin (in Chinese). Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1990;12:235-245.
83.
Xing EP, Nie Y, Song Y, Yang GY, et al: Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res 1999;5:2704-2713.
84.
Yang W-X, Lu X-X, Liu G-T, et al: Etiological prevention trial for esophageal cancer among high-risk population in Linzhou city, China. China Cancer 2008;17:548-552.
85.
Zeb MH, Baruah A, Kossak SK, Buttar NS: Chemoprevention in Barrett's esophagus: current status. Gastroenterol Clin North Am 2015;44:391-413.
86.
Heath EI, Canto MI, Piantadosi S, Montgomery E, et al: Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007;99:545-557.
87.
Leitzmann MF, Koebnick C, Freedman ND, Park Y, et al: Physical activity and esophageal and gastric carcinoma in a large prospective study. Am J Prev Med 2009;36:112-119.
88.
Yang P, Zhou Y, Chen B, Wan HW, et al: Aspirin use and the risk of gastric cancer: a meta-analysis. Dig Dis Sci 2010;55:1533-1539.
89.
Wei WQ, Chen ZF, He YT, Feng H, et al: Long-term follow-up of a community assignment, one-time endoscopic screening study of esophageal cancer in China. J Clin Oncol 2015;33:1951-1957.
90.
Small AJ, Araujo JL, Leggett CL, Mendelson AH, et al: Radiofrequency ablation is associated with decreased neoplastic progression in patients with Barrett's esophagus and confirmed low-grade dysplasia. Gastroenterology 2015;149:567-576.e3; quiz e13-e14.
91.
Wolf WA, Pasricha S, Cotton C, Li N, et al: Incidence of esophageal adenocarcinoma and causes of mortality after radiofrequency ablation of Barrett's esophagus. Gastroenterology 2015;149:1752-1761.e1.
92.
Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, et al: Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277-2288.
93.
Orman ES, Kim HP, Bulsiewicz WJ, Cotton CC, et al: Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation. Am J Gastroenterol 2013;108:187-195; quiz 196.
94.
Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, et al: Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 2011;141:460-468.
95.
Bennett C, Vakil N, Bergman J, Harrison R, et al: Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012;143:336-346.
96.
Haidry RJ, Lipman G, Banks MR, Butt MA, et al: Comparing outcome of radiofrequency ablation in Barrett's with high grade dysplasia and intramucosal carcinoma: a prospective multicenter UK registry. Endoscopy 2015;47:980-987.
97.
Li N, Pasricha S, Bulsiewicz WJ, Pruitt RE, et al: Effects of preceding endoscopic mucosal resection on the efficacy and safety of radiofrequency ablation for treatment of Barrett's esophagus: results from the United States Radiofrequency Ablation Registry. Dis Esophagus 2015, Epub ahead of print.
98.
van Vilsteren FG, Alvarez Herrero L, Pouw RE, Visser M, et al: Radiofrequency ablation and endoscopic resection in a single session for Barrett's esophagus containing early neoplasia: a feasibility study. Endoscopy 2012;44:1096-1104.
99.
Strauss AC, Agoston AT, Dulai PS, Srivastava A, Rothstein RI: Radiofrequency ablation for Barrett's-associated intramucosal carcinoma: a multi-center follow-up study. Surg Endosc 2014;28:3366-3372.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.